Business Wire: OverT Bio Announces the Formation of the Clinical Advisory Board to Support the Clinical Development of OVT-101 in Ovarian Cancer and Other Solid Tumors
NEW YORK--(BUSINESS WIRE)--OverT Bio, a biotechnology company developing next-generation therapies for solid tumors, today announced the formation of its Clinical Advisory Board, comprised of ...
OverT Bio Announces the Formation of the Clinical Advisory Board to Support the Clinical Development of OVT-101 in Ovarian Cancer and Other Solid Tumors
MSN: The translational power of liquid biopsy could improve clinical gynecologic oncology
The article, titled "Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice," presents a decisive shift from mere ...
Morningstar: Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
ascopubs.org: Improving outcomes in gyneco-oncology in late and last line setting: Real-world data from the molecular tumor board registry trial at the Comprehensive Cancer Center Freiburg ...
Improving outcomes in gyneco-oncology in late and last line setting: Real-world data from the molecular tumor board registry trial at the Comprehensive Cancer Center Freiburg ...
Physicians and scientists from Fred Hutch Cancer Center and UW Medicine are constantly researching, developing and testing new treatments for gynecologic cancers and new ways to use current treatments ...
Optimal surgical debulking to R0 remains a dominant prognostic determinant in ovarian cancer, while PARP inhibitor maintenance has become integral for BRCA-mutant and HRD-positive tumors.